RedHill Biopharma

RedHill RHB-104 gets FDA QIDP for Nontuberculous Mycobacteria Infections

Thursday, January 12, 2017

RedHill Biopharma, a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, has announced that RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) infections. The QIDP designation was granted under the FDA’s Generating Antibiotic Incentives Now (GAIN) Act, which is intended to encourage development of new antibiotic drugs for the treatment of serious or life-threatening infections.

[Read More]

RedHill Biopharma, Salix Pharmaceuticals ink license agreement

Friday, February 28, 2014

Salix Pharmaceuticals, a North Carolina-based developer and marketer of prescription pharmaceutical products and medical devices, and RedHill Biopharma, an emerging Israeli biopharmaceutical company, have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill’s RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.

[Read More]